Aerovate Therapeutics Stock Analysis

Aerovate Stock Analysis Notes

About 100.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Aerovate Therapeutics recorded a loss per share of 2.99. The entity had not issued any dividends in recent years. Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Aerovate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. For more info on Aerovate Therapeutics please contact Timothy MBA at 617 443 2400 or go to https://aerovatetx.com.

Aerovate Therapeutics Investment Alerts

Aerovate Therapeutics Upcoming and Recent Events

Aerovate Largest EPS Surprises

View All Earnings Estimates

Aerovate Therapeutics Environmental, Social, and Governance (ESG) Scores

Aerovate Stock Institutional Investors

Note, although Aerovate Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aerovate Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 76.81 M.

Aerovate Profitablity

Management Efficiency

Aerovate Therapeutics has return on total asset (ROA) of (0.4867) % which means that it has lost $0.4867 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8206) %, meaning that it created substantial loss on money invested by shareholders. Aerovate Therapeutics' management efficiency ratios could be used to measure how well Aerovate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 25, 2024, Return On Tangible Assets is expected to decline to -0.62. In addition to that, Return On Capital Employed is expected to decline to -0.78. At present, Aerovate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting.

Technical Drivers

As of the 25th of November, Aerovate Therapeutics shows the Mean Deviation of 2.55, downside deviation of 2.6, and Risk Adjusted Performance of 0.1393. Aerovate Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aerovate Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Aerovate Therapeutics is priced correctly, providing market reflects its regular price of 2.68 per share. Please also double-check Aerovate Therapeutics total risk alpha, which is currently at 0.0402 to validate the company can sustain itself at a future point.

Aerovate Therapeutics Price Movement Analysis

Aerovate Therapeutics Insider Trading Activities

Aerovate Therapeutics Outstanding Bonds

Aerovate Therapeutics Predictive Daily Indicators

Aerovate Therapeutics Corporate Filings

Aerovate Therapeutics Forecast Models

Aerovate Therapeutics' time-series forecasting models are one of many Aerovate Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aerovate Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aerovate Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aerovate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aerovate Therapeutics. By using and applying Aerovate Stock analysis, traders can create a robust methodology for identifying Aerovate entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aerovate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aerovate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Aerovate Therapeutics stock analysis indicators help investors evaluate how Aerovate Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aerovate Therapeutics shares will generate the highest return on investment. By understating and applying Aerovate Therapeutics stock analysis, traders can identify Aerovate Therapeutics position entry and exit signals to maximize returns.

When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.